Fundamental Analysis of ADDEX THERAPEUTICS LTD(NASDAQ:ADXN) stock

Fundamental Rating

ADXN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ADXN may be in some trouble as it scores bad on both profitability and health. ADXN shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ADXN has reported negative net income.

In the past year ADXN has reported a negative cash flow from operations.

In the past 5 years ADXN always reported negative net income.

ADXN had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

ADXN has a worse Return On Assets (-251.85%) than 92.15% of its industry peers.

Looking at the Return On Equity, with a value of -391.91%, ADXN is doing worse than 77.47% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-251.85%
ROE	-391.91%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADXN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.

ADXN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ADXN has an Altman-Z score of -76.79. This is a bad value and indicates that ADXN is not financially healthy and even has some risk of bankruptcy.

ADXN has a Altman-Z score of -76.79. This is amonst the worse of the industry: ADXN underperforms 96.25% of its industry peers.

ADXN has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.

ADXN has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: ADXN outperforms 41.98% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	-76.79

ROIC/WACCN/A

WACC5.44%

2.3 Liquidity

ADXN has a Current Ratio of 2.97. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.

ADXN's Current ratio of 2.97 is on the low side compared to the rest of the industry. ADXN is outperformed by 67.24% of its industry peers.

A Quick Ratio of 2.97 indicates that ADXN has no problem at all paying its short term obligations.

ADXN has a worse Quick ratio (2.97) than 65.87% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.97
Quick Ratio	2.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.23% over the past year.

Looking at the last year, ADXN shows a quite strong growth in Revenue. The Revenue has grown by 10.17% in the last year.

The Revenue has been growing by 23.65% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)68.23%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q60.6%

Revenue 1Y (TTM)10.17%

Revenue growth 3Y-20.11%

Revenue growth 5Y23.65%

Revenue growth Q2Q-20.8%

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.

ADXN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.56% yearly.

EPS Next Y-6.1%

EPS Next 2Y7.77%

EPS Next 3Y32.6%

EPS Next 5Y14.87%

Revenue Next Year213.81%

Revenue Next 2Y65.5%

Revenue Next 3Y110.65%

Revenue Next 5Y42.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADXN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADXN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ADXN's earnings are expected to grow with 32.60% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y7.77%

EPS Next 3Y32.6%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ADXN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (4/29/2024, 10:44:58 AM)

8.3

-7.8 (-48.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap8.79M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-251.85%
ROE	-391.91%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.4

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.97
Quick Ratio	2.97
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)68.23%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-6.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)10.17%

Revenue growth 3Y-20.11%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ADDEX THERAPEUTICS LTD (ADXN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens